Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GENIZ (Cambridge, Mass.) announced Phase II results with recombinant human interleukin-11, demonstrating a dose-dependent rise in platelet counts.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury